Hereditary Transthyretin Amyloidosis (hATTR) - Epidemiology Forecast - 2032

January 2022 | 60 pages | ID: HC422A1E1D50EN
DelveInsight

Abstracts

This report can be delivered to the clients within 5-7 Business Days

DelveInsight's 'Hereditary Transthyretin Amyloidosis (hATTR) - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Hereditary Transthyretin Amyloidosis (hATTR) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032

Hereditary Transthyretin Amyloidosis (hATTR) Understanding

The DelveInsight Hereditary Transthyretin Amyloidosis (hATTR) epidemiology report gives a thorough understanding of the Hereditary Transthyretin Amyloidosis (hATTR) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Hereditary Transthyretin Amyloidosis (hATTR) in the US, Europe, and Japan. The report covers the detailed information of the Hereditary Transthyretin Amyloidosis (hATTR) epidemiology scenario in seven major countries (US, EU5, and Japan).

Hereditary Transthyretin Amyloidosis (hATTR) Epidemiology Perspective by DelveInsight

The Hereditary Transthyretin Amyloidosis (hATTR) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Hereditary Transthyretin Amyloidosis (hATTR) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Hereditary Transthyretin Amyloidosis (hATTR) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Hereditary Transthyretin Amyloidosis (hATTR) Detailed Epidemiology Segmentation

The Hereditary Transthyretin Amyloidosis (hATTR) epidemiology covered in the report provides historical as well as forecasted Hereditary Transthyretin Amyloidosis (hATTR) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

The DelveInsight Hereditary Transthyretin Amyloidosis (hATTR) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

• The Hereditary Transthyretin Amyloidosis (hATTR) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Hereditary Transthyretin Amyloidosis (hATTR) Epidemiology Report and Model provide an overview of the global trends of Hereditary Transthyretin Amyloidosis (hATTR) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight into the historical and forecasted patient pool of Hereditary Transthyretin Amyloidosis (hATTR) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps recognize the growth opportunities in the 7MM for the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Hereditary Transthyretin Amyloidosis (hATTR)
• The report provides the segmentation of the Hereditary Transthyretin Amyloidosis (hATTR) epidemiology

Report Highlights

• 11-year Forecast of Hereditary Transthyretin Amyloidosis (hATTR) epidemiology
• 7MM Coverage
• Prevalent and Diagnosed Cases of Hereditary Transthyretin Amyloidosis (hATTR)
• Cases of Hereditary Transthyretin Amyloidosis (hATTR) by Mutation Types
• Hereditary Transthyretin Amyloidosis (hATTR) Cases associated with Clinical Manifestations

KOL views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Hereditary Transthyretin Amyloidosis (hATTR)?
• What are the key findings pertaining to the Hereditary Transthyretin Amyloidosis (hATTR) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)?
• What would be the total number of patients of Hereditary Transthyretin Amyloidosis (hATTR) across the 7MM during the forecast period (2019-2032)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
• What is the disease risk, burden and unmet needs of Hereditary Transthyretin Amyloidosis (hATTR)?
• What are the currently available treatments of Hereditary Transthyretin Amyloidosis (hATTR)?

Reasons to buy

The Hereditary Transthyretin Amyloidosis (hATTR) Epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global Hereditary Transthyretin Amyloidosis (hATTR) market
• Quantify patient populations in the global Hereditary Transthyretin Amyloidosis (hATTR) market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Hereditary Transthyretin Amyloidosis (hATTR) therapeutics in each of the markets covered
• Understand the magnitude of Hereditary Transthyretin Amyloidosis (hATTR) population by its epidemiology
• The Hereditary Transthyretin Amyloidosis (hATTR) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Contents

1. KEY INSIGHTS

2. EXECUTIVE SUMMARY OF HEREDITARY TRANSTHYRETIN AMYLOIDOSIS (HATTR)

3. HEREDITARY TRANSTHYRETIN AMYLOIDOSIS (HATTR): DISEASE BACKGROUND AND OVERVIEW

3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis

4. PATIENT JOURNEY

5. EPIDEMIOLOGY AND PATIENT POPULATION

5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
  5.3.1. Hereditary Transthyretin Amyloidosis (hATTR) Epidemiology Scenario in the 7MM (2019- 2032)
5.4. United States Epidemiology
  5.4.1. Hereditary Transthyretin Amyloidosis (hATTR) Epidemiology Scenario in the United States (2019- 2032)
5.5. EU-5 Country-wise Epidemiology
  5.5.1. Germany Epidemiology
    5.5.1.1. Hereditary Transthyretin Amyloidosis (hATTR) Epidemiology Scenario in Germany (2019- 2032)
  5.5.2. France Epidemiology
    5.5.2.1. Hereditary Transthyretin Amyloidosis (hATTR) Epidemiology Scenario in France (2019- 2032)
  5.5.3. Italy Epidemiology
    5.5.3.1. Hereditary Transthyretin Amyloidosis (hATTR) Epidemiology Scenario in Italy (2019- 2032)
  5.5.4. Spain Epidemiology
    5.5.4.1. Hereditary Transthyretin Amyloidosis (hATTR) Epidemiology Scenario in Spain (2019- 2032)
  5.5.5. United Kingdom Epidemiology
    5.5.5.1. Hereditary Transthyretin Amyloidosis (hATTR) Epidemiology Scenario in the United Kingdom (2019-2032)
5.6. Japan Epidemiology
  5.6.1. Hereditary Transthyretin Amyloidosis (hATTR) Epidemiology Scenario in Japan (2019- 2032)

6. TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES

6.1. Hereditary Transthyretin Amyloidosis (hATTR) Treatment and Management
6.2. Hereditary Transthyretin Amyloidosis (hATTR) Treatment Algorithm

7. KOL VIEWS

8. UNMET NEEDS

9. APPENDIX

9.1. Bibliography
9.2. Report Methodology

10. DELVEINSIGHT CAPABILITIES

11. DISCLAIMER

12. ABOUT DELVEINSIGHT

*The table of contents is not exhaustive; will be provided in the final report

List Of Tables

LIST OF TABLES

List of Table:
Table 1: Hereditary Transthyretin Amyloidosis (hATTR) Epidemiology in 7MM (2019-2032)
Table 2: Hereditary Transthyretin Amyloidosis (hATTR) Diagnosed and Treatable Cases in 7MM (2019-2032)
Table 3: Hereditary Transthyretin Amyloidosis (hATTR) Epidemiology in the United States (2019-2032)
Table 4: Hereditary Transthyretin Amyloidosis (hATTR) Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: Hereditary Transthyretin Amyloidosis (hATTR) Epidemiology in Germany (2019-2032)
Table 6: Hereditary Transthyretin Amyloidosis (hATTR) Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: Hereditary Transthyretin Amyloidosis (hATTR) Epidemiology in France (2019-2032)
Table 8: Hereditary Transthyretin Amyloidosis (hATTR) Diagnosed and Treatable Cases in France (2019-2032)
Table 9: Hereditary Transthyretin Amyloidosis (hATTR) Epidemiology in Italy (2019-2032)
Table 10: Hereditary Transthyretin Amyloidosis (hATTR) Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: Hereditary Transthyretin Amyloidosis (hATTR) Epidemiology in Spain (2019-2032)
Table 12: Hereditary Transthyretin Amyloidosis (hATTR) Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: Hereditary Transthyretin Amyloidosis (hATTR) Epidemiology in the United Kingdom (2019-2032)
Table 14: Hereditary Transthyretin Amyloidosis (hATTR) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Table 15: Hereditary Transthyretin Amyloidosis (hATTR) Epidemiology in Japan (2019-2032)
Table 16: Hereditary Transthyretin Amyloidosis (hATTR) Diagnosed and Treatable Cases in Japan (2019-2032)

List Of Figures

LIST OF FIGURES

List of Figures
Figure 1 Hereditary Transthyretin Amyloidosis (hATTR) Epidemiology in 7MM (2019-2032)
Figure 2 Hereditary Transthyretin Amyloidosis (hATTR) Diagnosed and Treatable Cases in 7MM (2019-2032)
Figure 3 Hereditary Transthyretin Amyloidosis (hATTR) Epidemiology in the United States (2019-2032)
Figure 4 Hereditary Transthyretin Amyloidosis (hATTR) Diagnosed and Treatable Cases in the United States (2019-2032)
Figure 5 Hereditary Transthyretin Amyloidosis (hATTR) Epidemiology in Germany (2019-2032)
Figure 6 Hereditary Transthyretin Amyloidosis (hATTR) Diagnosed and Treatable Cases in Germany (2019-2032)
Figure 7 Hereditary Transthyretin Amyloidosis (hATTR) Epidemiology in France (2019-2032)
Figure 8 Hereditary Transthyretin Amyloidosis (hATTR) Diagnosed and Treatable Cases in France (2019-2032)
Figure 9 Hereditary Transthyretin Amyloidosis (hATTR) Epidemiology in Italy (2019-2032)
Figure 10 Hereditary Transthyretin Amyloidosis (hATTR) Diagnosed and Treatable Cases in Italy (2019-2032)
Figure 11 Hereditary Transthyretin Amyloidosis (hATTR) Epidemiology in Spain (2019-2032)
Figure 12 Hereditary Transthyretin Amyloidosis (hATTR) Diagnosed and Treatable Cases in Spain (2019-2032)
Figure 13 Hereditary Transthyretin Amyloidosis (hATTR) Epidemiology in the United Kingdom (2019-2032)
Figure 14 Hereditary Transthyretin Amyloidosis (hATTR) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Figure 15 Hereditary Transthyretin Amyloidosis (hATTR) Epidemiology in Japan (2019-2032)
Figure 16 Hereditary Transthyretin Amyloidosis (hATTR) Diagnosed and Treatable Cases in Japan (2019-2032)
*The table of contents is not exhaustive; will be provided in the final report